Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

GMA-106 is under development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). The drug candidate is being developed based on Bibody platform. It acts by ...

CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

MyMD-1 is under clinical development by TNF Pharmaceuticals and currently in Phase I for Hashimoto Thyroiditis.

Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase I for Kaposi Sarcoma.

Q-901 is under clinical development by Qurient and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase ...

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Immunological Disorders.

Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).